Table 4.
Circulating matrix metalloprotease 7 was associated with greater risk of eGFR decline by 50% or ESKD in Atherosclerosis Risk In Communities participants at visit 2
| Outcome | Model | Non-DM (n=9407) | DM (n=1623) | ||||
|---|---|---|---|---|---|---|---|
| Events | HR (95% CI) | P Value | Events | HR (95% CI) | P Value | ||
| eGFR 50% decline | Model 1 | 1190 | 1.35 (1.23 to 1.48) | 3.20E-10 | 354 | 2.28 (1.92 to 2.70) | 4.44E-21 |
| eGFR 50% decline | Model 2 | 1190 | 1.24 (1.13 to 1.35) | 3.66E-06 | 354 | 1.77 (1.48 to 2.11) | 2.33E-10 |
| eGFR 50% decline | Model 3 | 1190 | 1.17 (1.05 to 1.29) | 2.94E-03 | 354 | 1.68 (1.40 to 2.01) | 1.79E-08 |
| ESKD | Model 1 | 131 | 3.94 (3.09 to 5.03) | 3.93E-28 | 153 | 3.78 (3.00 to 4.77) | 1.95E-29 |
| ESKD | Model 2 | 131 | 2.01 (1.51 to 2.69) | 1.96E-06 | 153 | 2.01 (1.54 to 2.62) | 3.27E-07 |
| ESKD | Model 3 | 131 | 2.15 (1.60 to 2.89) | 3.23E-07 | 153 | 1.77 (1.35 to 2.32) | 3.26E-05 |
Model 1 was adjusted for age, sex, and race/center; model 2 was additionally adjusted for systolic blood pressure, antihypertensive medications, prevalent cardiovascular disease, smoking status, eGFRcrcys, HDL cholesterol levels, and total cholesterol levels; model 3 was adjusted for all previously mentioned covariates along with the first five principal components of the proteomics data. All hazard ratios are expressed per doubling of the protein level. DM, diabetes mellitus; HR, hazard ratio; CI, confidence interval.